Trial Outcomes & Findings for The Use of an "Anal-Tape" in Patients With Fecal Incontinence (NCT NCT02989545)

NCT ID: NCT02989545

Last Updated: 2020-04-02

Results Overview

The FIQoL is a validated, condition-specific tool that evaluates quality of life (QoL) in patients with fecal incontinence (FI) it consisting of 29 questions, subdivided into four domains: Lifestyle, Coping/Behavior, Depression/Self-perception, and Embarrassment. Item 1, general health, is graded from 1 "excellent" to 5 "poor" and is reversely scored. Items 2 to 28 are graded on a 4-point Likert-scale (1 = lower QoL). Item 29, FI specific depression, is graded from 1 "extremely so" to 6 "not at all." The average score for each domain is calculated separately and is calculated only if half or more of the items in the particular domain have been answered. Scales range from 1 to 5, with a 1 indicating a lower quality of life. Each domain or subscale is reported separately (Range 1 to 5), a total score including all four domains is not calculated.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

2 weeks

Results posted on

2020-04-02

Participant Flow

Participant milestones

Participant milestones
Measure
Per Sequence
Off treatment first for 14 days Treatment period second for 14 days
Control Period - no Intervention
STARTED
20
Control Period - no Intervention
COMPLETED
20
Control Period - no Intervention
NOT COMPLETED
0
Treatment Period - Anal Tape Provided
STARTED
20
Treatment Period - Anal Tape Provided
COMPLETED
20
Treatment Period - Anal Tape Provided
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Use of an "Anal-Tape" in Patients With Fecal Incontinence

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Patients
n=20 Participants
2 week period without intervention then 2 week period with anal tape intervention
Age, Continuous
64 years
n=99 Participants
Sex: Female, Male
Female
20 Participants
n=99 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
Race (NIH/OMB)
White
0 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
20 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 2 weeks

The FIQoL is a validated, condition-specific tool that evaluates quality of life (QoL) in patients with fecal incontinence (FI) it consisting of 29 questions, subdivided into four domains: Lifestyle, Coping/Behavior, Depression/Self-perception, and Embarrassment. Item 1, general health, is graded from 1 "excellent" to 5 "poor" and is reversely scored. Items 2 to 28 are graded on a 4-point Likert-scale (1 = lower QoL). Item 29, FI specific depression, is graded from 1 "extremely so" to 6 "not at all." The average score for each domain is calculated separately and is calculated only if half or more of the items in the particular domain have been answered. Scales range from 1 to 5, with a 1 indicating a lower quality of life. Each domain or subscale is reported separately (Range 1 to 5), a total score including all four domains is not calculated.

Outcome measures

Outcome measures
Measure
Off Treatment
n=20 Participants
2 week period without intervention
Treatment Period
n=20 Participants
2 week period with intervention - Anal tape
Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs)
Lifestyle
2.8 score on a scale
Standard Deviation 0.69
3.3 score on a scale
Standard Deviation 0.68
Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs)
Coping/Behaivoir
1.9 score on a scale
Standard Deviation 0.64
2.5 score on a scale
Standard Deviation 0.73
Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs)
Depression/Self-Perception
3.1 score on a scale
Standard Deviation 0.75
3.5 score on a scale
Standard Deviation 0.74
Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs)
Embarrassment
2.13 score on a scale
Standard Deviation 0.67
2.65 score on a scale
Standard Deviation 0.76

SECONDARY outcome

Timeframe: 4 weeks

Population: Note that this outcome was obtained by free text stool diaries that patients had to keep at home. Only 15 patient out of 20 provided full diaries, therefore the analysis is limited to 15 instead of all 20.

Number of pateints with reduction of more than 50% in the absolute number of FI events during each week of the study

Outcome measures

Outcome measures
Measure
Off Treatment
n=15 Participants
2 week period without intervention
Treatment Period
n=15 Participants
2 week period with intervention - Anal tape
A 50% Reduction in the Number of Episodes of FI Per Week
0 Participants
5 Participants

SECONDARY outcome

Timeframe: 2 weeks

The Wexner Scale is a measure of frequency and severity of anal incontinence. It comprises five items, three regarding frequency of involuntary passage of gas, liquid, or solid stool, frequency of pad wearing, and frequency of lifestyle alteration, scored in a 5-point Likert-scale (never=0, rarely=1, sometimes=2, usually=3, always=4). A sum of all scores from 0 to 20 is calculated with higher scores meaning more severe incontince.

Outcome measures

Outcome measures
Measure
Off Treatment
n=20 Participants
2 week period without intervention
Treatment Period
n=20 Participants
2 week period with intervention - Anal tape
Mean Wexner Score
11.9 score on a scale
Standard Deviation 3.5
10.3 score on a scale
Standard Deviation 4.8

SECONDARY outcome

Timeframe: 2 weeks

The Wexner Scale is a measure of frequency and severity of anal incontinence. It comprises five items, three regarding frequency of involuntary passage of gas, liquid, or solid stool, frequency of pad wearing, and frequency of lifestyle alteration, scored in a 5-point Likert-scale (never=0, rarely=1, sometimes=2, usually=3, always=4). A sum of all scores from 0 to 20 is calculated with higher scores meaning more severe incontince.

Outcome measures

Outcome measures
Measure
Off Treatment
n=20 Participants
2 week period without intervention
Treatment Period
n=20 Participants
2 week period with intervention - Anal tape
Mean Redction in Wexner Scale Compared to Baseline
0.6 score on a scale
Standard Deviation 1.7
1.95 score on a scale
Standard Deviation 4.2

SECONDARY outcome

Timeframe: 2 weeks

Population: Note that in 3 patients these data were missing, therefore the analysis if for 17 out of 20 participants.

General satisfaction with the device was assessed using a standard 100 mm visual analog scale. Patients were asked to grade their satisfaction with the device between 0 and 100 by drawing a perpendicular line in the 100 mm visual analog scale. Then the distance in mm was measured in mm from 0 to the perpendicular line and the score was calculated. Higher scores meaning better satisfaction.

Outcome measures

Outcome measures
Measure
Off Treatment
n=17 Participants
2 week period without intervention
Treatment Period
2 week period with intervention - Anal tape
General Satisfaction
80 mm in VAS scale
Interval 50.0 to 90.0

SECONDARY outcome

Timeframe: 4 weeks

Population: Note that in 3 patients these data were missing, therefore the analysis if for 17 out of 20 participants.

Willingness of the patient to continue using the device was assessed using a standard 100 mm visual analog scale. Patients were asked to grade their willingness to use the device in the future between 0 and 100 by drawing a perpendicular line in the 100 mm visual analog scale. Then the distance in mm was measured in mm from 0 to the perpendicular line and the score was calculated. Higher scores meaning better satisfaction.

Outcome measures

Outcome measures
Measure
Off Treatment
n=17 Participants
2 week period without intervention
Treatment Period
2 week period with intervention - Anal tape
Willingness of the Patient to Continue Using the Anal Tape After the Study.
90 mm in VAS scale
Interval 50.0 to 90.0

Adverse Events

Control Period - No Intervention

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Treatment Period - Anal Tape Provided

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Control Period - No Intervention
n=20 participants at risk
Consiting of the first 14 days of the study during which patients were off treatment and baseline and safety data was collected
Treatment Period - Anal Tape Provided
n=20 participants at risk
Consiting of the second 14 days of the study (day 15 to 28) during which patients were provided with the "anal tape" device and during this period efficacy and safety data was collected.
Gastrointestinal disorders
Mild difficulty to remove the device
0.00%
0/20 • 4 weeks study period
15.0%
3/20 • Number of events 3 • 4 weeks study period

Additional Information

Dr. Dan Livovsky

Shaare Zedek Medical Center

Phone: +972525622398

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place